advertisement
Abstract #6473 Published in IGR 3-2
Ocular hypotensive efficacy and safety of once daily carteolol alginate
Demailly P; Allaire C; Trinquand CBritish Journal of Ophthalmology 2001; 85: 921-924
BACKGROUND/AIM: Carteolol is a β adrenoceptor antagonist used topically to reduce intraocular pressure (IOP), typically twice daily. In an effort to provide a once-daily dosing regimen, carteolol was formulated with 1% alginic acid. The objective of this study was to evaluate the efficacy and safety of carteolol alginate solution compared to standard carteolol solution. METHODS: This was a double masked, parallel group, multicenter study. Patients with ocular hypertension or open-angle glaucoma (n = 235) were randomly assigned to receive either carteolol alginate four times daily or standard carteolol solution twice daily. The masking was maintained through the use of a vehicle in the evening for the alginate group. Patients were evaluated at baseline, and at 15, 60, and 120 days. RESULTS: At 09.00 (presumed trough) on Day 60, mean reductions in IOP from baseline were 6.09 (SD 2.97) and 6.09 (3.18) mmHg for the standard carteolol and alginate, respectively. At 11.00 (presumed peak), mean reductions were 6.51 (2.53) and 6.47 (2.76) mmHg, respectively. Results were similar at other times (Days 15 and 120). The most common side-effect was transient stinging on instillation of drops, which did not differ significantly between groups. There were no differences of note in other ocular or systemic signs or symptoms. CONCLUSIONS: The new alginate formulation of carteolol 2% given once daily was as effective as standard carteolol 2% given twice daily with no meaningful differences regarding safety.
Dr C. Trinquand, Laboratoire Chauvin, Scientific and Medical Affairs Department, Le Millenaire, BP 1174, F-34009 Montpellier cedex, France. ctrinquand@chauvingroup.com
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
